Market Access Advancements and Challenges in "Drug-Companion Diagnostic Test" Co-Development in Europe

The pharma ecosphere is witnessing a measured transformation from the one-size-fits-all or blockbuster model of drugs to more informed and tailored personalized treatments that facilitate higher safety and efficacy for a relevant sub-population. However, with several breakthroughs still in a nascent...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of personalized medicine Vol. 5; no. 2; pp. 213 - 228
Main Authors:	Akhmetov, Ildar, Ramaswamy, Rakshambikai, Akhmetov, Illias, Thimmaraju, Phani Kishore
Format:	Journal Article Book Review
Language:	English
Published:	Switzerland MDPI AG 12-06-2015 MDPI
Subjects:	Precision medicine Review value addition cost-effectiveness market access Stratified medicine companion diagnostics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The pharma ecosphere is witnessing a measured transformation from the one-size-fits-all or blockbuster model of drugs to more informed and tailored personalized treatments that facilitate higher safety and efficacy for a relevant sub-population. However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders. This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution. Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	2075-4426 2075-4426
DOI:	10.3390/jpm5020213